恩扎鲁胺诱导宿主代谢重编程与去势抵抗性前列腺癌治疗结局相关
Enzalutamide‐Induced Host Metabolic Reprogramming Is Associated with Treatment Outcomes in Patients with Castration‐Resistant Prostate Cancer: A Hypothesis‐Generating Study
作者：Giuseppe Corona、Michele Visentin、Sophia Leonie Samodelov、Francesca Maines、Orazio Caffo、Gianmaria Miolo
单位：Immunopathology and Cancer Biomarkers Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.；Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.；Medical Oncology Department, Santa Chiara Hospital, APSS, Trento, Italy.；Medical Oncology and Cancer Prevention Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.
摘要
《临床药理学与治疗学》发表一项假设生成性研究，评估恩扎鲁胺治疗去势抵抗性前列腺癌（CRPC）患者时诱导的宿主代谢重编程及其与治疗结局的关联。研究提示代谢变化可能作为疗效预测标志物，为优化个体化治疗提供新方向。该研究为早期探索，尚需前瞻性验证。
AI 主编 · 推荐理由推荐理由
对肿瘤药企临床研发具有启发意义：代谢标志物或可助力恩扎鲁胺及同类药物的患者筛选和疗效预测，建议关注后续验证性研究以评估转化价值。